Know Labs, Inc. (KNW)
| Previous close | 0.6186 |
| Open | 0.6100 |
| Bid | 0.6000 x 1000 |
| Ask | 0.6200 x 1800 |
| Day's range | 0.6038 - 0.6099 |
| 52-week range | 0.2300 - 1.4800 |
| Volume | |
| Avg. volume | 134,917 |
| Market cap | 50.324M |
| Beta (5Y monthly) | 1.56 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3700 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.00 |
Business WireKnow Labs to Present Clinical Research at the 2024 American Physiology Summit
SEATTLE, April 05, 2024--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an abstract poster presentation at the American Physiological Society (APS) Summit in Long Beach, California on April 4-7, 2024.
Business WireKnow Labs’ Non-Invasive Glucose Monitor Achieves 11.1% MARD in Latest Clinical Research Study
SEATTLE, March 06, 2024--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced interim results from its most recent clinical research study. The study assessed the accuracy of Know Labs’ proprietary radiofrequency (RF) dielectric sensor in non-invasively measuring blood glucose in participants with prediabetes and Type 2 diabetes using venous blood as a comparative reference – resulting in an overall Mean Absolute Relative Diff
Business WireKnow Labs Secures U.S. $12 Million Funding for Company’s Further Execution on Its Clinical Research and Development Initiatives
SEATTLE, February 29, 2024--Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has entered into a funding agreement for an investment of up to $12 million, of which it has executed a $4 million close (the "Funding Agreement") with Lind Global Fund II LP, an investment entity managed by The Lind Partners, a New York-based institutional fund manager (together, "Lind").
